<DOC>
	<DOCNO>NCT00095329</DOCNO>
	<brief_summary>The purpose study determine safety tolerability drug sirolimus patient multiple sclerosis ( MS ) fail treatment .</brief_summary>
	<brief_title>Treating Multiple Sclerosis With Sirolimus , Immune System Suppressor</brief_title>
	<detailed_description>MS chronic autoimmune disease central nervous system myelin , protein sheath protects nerve cell , degrade T cell macrophage , lead eventual loss neurologic function . MS classify either relapsing-remitting , patient experience worsen symptom follow partial complete recovery function ; progressive , patient gradual increase symptom , without relapse . Standard treatment use treat relapsing-remitting MS modestly effective may associate significant toxicity . There need develop therapy low toxicity administer early course disease potential stop disease progression altogether . Sirolimus demonstrate provide potent immunosuppression recent clinical trial involve kidney transplantation , may help people autoimmune disease like MS . This study determine benefit sirolimus MS patient . Blood urine collection occur screen . Participants take daily dos sirolimus 6 month . There nine study visit ; occur Days 14 , 28 , 42 , 56 , 90 , 120 , 150 , 180 , 225 . Medication adverse event , concomitant medication , vital sign record Visits 1 8 . At visit , patient compliance sirolimus regimen measure , blood urine collection occur . Physical neurological exam , magnetic resonance imaging ( MRI ) brain scan , MS status test , chest x-ray conduct select time throughout study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Relapsingremitting MS Evidence demyelination magnetic resonance imaging ( MRI ) scan Expanded Disability Status Scale ( EDSS ) score 0 6 Nonresponsive betainterferon Glatiramer acetate therapy Discontinuation betainterferon Glatiramer acetate therapy within 1 month prior study entry Willing use acceptable method contraception Primary progressive MS Prior treatment immunosuppressant Steroid therapy within 1 month prior study entry Evidence active infection cancer Heart hematologic dysfunction High level lipid blood Use lipidlowering agent History cirrhosis liver disease require treatment History hepatitis B C Active cytomegalovirus infection Kidney disease require treatment Active lung disease Diabetes Hyperthyroidism HIV infection Tuberculosis History alcohol drug abuse within 6 month prior study entry Claustrophobia inability undergo MRI Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>relapsing-remitting MS</keyword>
	<keyword>nonresponsive standard care MS</keyword>
	<keyword>sirolimus</keyword>
</DOC>